Analyst firms · Morgan Stanley · MRVI
Morgan Stanley MRVI price target and rating history
Maravai LifeSciences Holdings Inc. (MRVI) · Health Care
Morgan Stanley rates Maravai LifeSciences Holdings Inc. (MRVI) Equal-Weight with a $10 price target, as of its latest action on Aug 13, 2024. It has published 3 rating actions on MRVI since August 2021, including 0 upgrades and 1 downgrade.
- Current rating
- Equal-Weight
- Price target
- $10
- Median target, all firms
- Too few
- Actions on MRVI
- 3
Morgan Stanley price target on MRVI
Every Morgan Stanley rating on MRVI
- Aug 13, 2024
- Feb 25, 2022
- Aug 12, 2021
How other firms rate MRVI
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| KeyBanc Capital Markets | Overweight | $11 | Nov 12, 2026 |
| TD Cowen | Buy | $9 | Oct 5, 2026 |
Questions about Morgan Stanley and MRVI
- What is Morgan Stanley's price target for MRVI?
- Morgan Stanley's latest stated price target for Maravai LifeSciences Holdings Inc. (MRVI) is $10, from its action on Aug 13, 2024.
- What is Morgan Stanley's rating on MRVI?
- Morgan Stanley rates MRVI Equal-Weight, a neutral rating, as of Aug 13, 2024.
- When did Morgan Stanley last change its view on MRVI?
- On Aug 13, 2024, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $11 to $10.
More MRVI rating histories
All Morgan Stanley ratingsMRVI news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.